Hints and tips:
Related Special Reports
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
...Pfizer will not take the twice-daily formulation into late-stage trials but will focus on developing a pill to be taken once a day....
...data from analytics group Airfinity shows European countries including the UK, France, Spain and Italy could have made the medication more accessible without using up supplies, as more than 1.5mn five-day...
...Shares in Amgen ended the day largely flat, while Horizon rose 2.3 per cent....
...The next day, Pfizer’s shares rose by more than 10 per cent on the news, in the largest single-day price move for the stock in more than a decade....
...“Those days are ending,” he said....
...One Passi at the time for Morgan Stanley’s new chief Morgan Stanley’s new chief executive Ted Pick officially took over from predecessor James Gorman on New Year’s Day....
...The New Jersey pharmaceutical titan’s share price has doubled in the past five years, well ahead of the wider S&P 500 index....
...Last week, a verdict was passed down in the case of Walkers Snack Foods Ltd v Commissioners for His Majesty’s Revenue and Customs, with first-tier tribunal judges Anne Fairpo and Sonia Gable ruling against...
...The incident occurred on the same day that the executive and another male employee drank beer throughout a work meeting in which Tantum was pitching to be promoted, she claimed....
...Less than 10 days later, the FTC said it would intensify enforcement against illicit rebate plans or bribes to prescription drug intermediaries that block consumers’ access to low-cost drugs....
...Inflammatory disease specialist Acelyrin is set to provide a further test for the beleaguered listings market in the coming days with the largest biotech IPO since June 2021....
...It’s something that will probably come while I’m chair but if possible in the later years,” he said of the day when Soriot eventually departs....
...The FT’s US pharmaceutical correspondent Jamie Smyth helps us explore whether J&J’s use of this manoeuvre is setting a precedent for corporations to evade accountability in America....
...In a letter to Illumina shareholders seen by the Financial Times, Icahn alleges that on the day before closing the deal Illumina directors required that the company commit to provide them with an “unprecedented...
...These days, consumer-facing healthcare companies — a slow-growth, low-margin yet steady business — tend to fetch higher valuations....
...It also generated excitement across the pharmaceutical industry, which is enticed by the prospect of selling medicines to the more than 50mn people worldwide who suffer from the disease....
...In November Amgen published early-stage trial data showing patients on a high dose of its drug candidate Amgen 133 lost almost 15 per cent of body weight in just 85 days....
...Illumina shares ended the day 17 per cent higher at $226.94 in New York....
...The very real cost is lives lost with every day of delay.”...
...“We kind of cheer a little bit of volatility in the market,” says Day....
...J&J hired Jones Day, a Cleveland-based law firm and author of the “Texas two-step”....
...Hillhouse InvestmentO: 7; L: 7; I: 7; Total: 21The private equity firm’s legal team worked with software developers to create an online portal combining several applications to help on day-to-day work, such...
...On average molnupiravir cut the duration of symptoms by about four days....
...Janssen is the pharmaceutical division of J&J....
International Edition